EHDS for pharma: A complete guide 

Executive summary

• For pharma leaders, that has direct implications for clinical trial feasibility, real-world evidence, AI development, compliance traceability, and cross-border research
• The real shift is operational. The EHDS moves the industry from fragmented and often manual data access processes toward more governed, repeatable, and scalable workflows
• Teams that prepare early can turn EHDS readiness into an advantage through better governance, stronger auditability, and faster execution
• The EHDS is projected to accelerate clinical trial timelines by 14%, get life-saving medicines to market around 3 to 6 months faster, and save 30% in research costs
• Implementation will be phased, with key milestones starting from 2029 and extending into 2031 and beyond
• Industry advisers and pharma-focused groups are already urging life sciences teams to treat the EHDS as a near-term readiness issue, not a distant regulatory change

For pharma leaders, it is easy to frame the European Health Data Space (EHDS) as another EU regulation. But that is too narrow a way to look at it. 

The EHDS matters because it changes the conditions for how health data can be discovered, accessed, governed, and used across Europe. As the European Commission explains, it creates a common framework for the exchange and secure reuse of electronic health data across the EU¹.

The impact is significant for EU healthcare research. It is expected to affect more than 200 university hospitals, thousands of other healthcare and research organizations, and tens of thousands of data users across Europe.

For pharma, the question is not only compliance. More consistent, governed, and repeatable access to health data through defined access mechanisms can support trial planning, evidence generation, AI development, and cross-border collaboration under clear conditions. In practice, the EHDS represents a shift from fragmented access models toward a more industrialized and governed way of working with health data.

Why the EHDS matters for pharma 

Pharma teams are under pressure from several directions at once. They need stronger evidence, faster innovation, more efficient trial execution, clearer governance, and more confidence in how data and analytics are used.

The EHDS matters because it is designed to reduce structural friction in European health data access.¹ This is achieved by introducing a more standardized system for requesting and authorizing access, where data remains with data holders and is accessed through health data access bodies and secure processing environments.

Today, pharma teams often work across fragmented national rules, different access bodies, inconsistent governance models, and highly manual workflows.² That slows research, adds operational risk, and makes scaling difficult.^1,2

For pharma, the opportunity lies in being able to operate more efficiently within this more structured and standardized access model. By improving the consistency and scalability of data access and reuse, the EHDS is projected to accelerate clinical trial timelines by 14%, get life-saving medicines to market around 3 to 6 months faster, and save 30% in research costs.³

Industry groups and advisers are already making the same point: pharma should treat the EHDS as a near-term readiness issue, not a distant regulatory change. EFPIA has highlighted both the opportunities and implementation challenges for pharma, while legal and advisory firms have urged life sciences companies to begin assessing data, infrastructure, governance, and third-party arrangements ahead of the 2029 milestones.^8,10,11,12

The implications go beyond pure compliance. As health data access becomes more standardized, governed, and mediated across Europe, pharma teams can improve speed, reduce redundant work efforts, and build stronger evidence programs. This direction also aligns with how the European Medicines Agency (EMA) frames real-world evidence as an increasingly important part of regulatory decision making.⁴

This does not change who holds the data. Health data remains with data holders such as healthcare providers and registries. Instead, the EHDS introduces a standardized framework where data users such as pharma apply to health data access bodies to obtain permission to use data for defined purposes. This shift, from fragmented and case-by-case processes to a more consistent and regulated framework, is expected to reduce repeated country-by-country applications, repeated approvals and study setup work, while enabling more streamlined, reusable workflows and shorter approval timelines.

The EHDS regulation overview 

The EHDS introduces a new EU-level framework for using and moving healthcare data across Europe. At a high level, it covers two major areas: 

• EHDS1, primary use of health data across EU countries 
• EHDS2, secondary use of health data across EU countries 

Together, these create a more common framework for health data discovery, access, and reuse.

The regulation introduces responsibilities for data holders, data users, health data access bodies, and secure processing environments. It is designed to support more standardized workflows for discovery, access, approval, analysis, and controlled output handling. The European Commission’s EHDS overview and formal regulation timeline make it clear that this is intended as an EU-wide operating framework, not just a policy signal.^1,5

The implications for pharma are simple. The EHDS is not just new legislation – it’s a new operating context for evidence generation in Europe. 

The EHDS timeline, phased rollout, and funding 

Copilot said:

The timeline is now clear enough that pharma teams should treat preparation as an active priority. The EHDS was approved in 2024 and entered into force in 2025, with phased application from 2029 onward. The European Commission provides further detail on the implementation timeline.^1,5 

The key milestones are: 

• March 2025, the EHDS Regulation enters into force, and the transition period begins 
• March 2027, the Commission is due to adopt several key implementing acts 
• March 2029, major rules start to apply for the first primary use categories and for most secondary use categories, including data from electronic health records 
• March 2031, additional primary use categories such as medical images, lab results, and hospital discharge reports should be operational, and secondary use expands to remaining categories such as genomic data 
• March 2035, third countries and international organizations can apply to join HealthData@EU for secondary use 

Our EHDS readiness guide is directionally aligned with this longer transition, highlighting early readiness work now, full compliance planning across the coming years, omics readiness as a later phase, and eventual access beyond the EU.⁶

Funding also matters. EU-level funding of approximately €810 million, provided by the European Union, is intended to support the development of the infrastructure required for the EHDS, including health data access bodies, interoperability, and secure processing environments alongside broader digital health and national funding mechanisms that support the transition.⁷

This funding supports the development of the underlying infrastructure rather than directly funding pharma research. For pharma, this investment enables more consistent, scalable, and cross-border data access in practice.

Why the EHDS matters for compliance, traceability, and audit readiness 

The EHDS increases expectations for governed, traceable, and defensible digital health data workflows. For pharma, this means being able to show who accessed what, why, when, and under which approval. Evidence packages should not need to be reconstructed manually after the fact. They should be generated from controlled workflows with clear governance and logging. 

This is especially relevant for AI-supported analytics and secondary use programs, where organizations need clear control around permitted use, data lineage, activity tracking, and output handling. That broader shift is also reflected in how industry groups such as EFPIA discuss EHDS opportunities and challenges for pharma, especially around access, trust, governance, and implementation complexity.⁸

This is also why readiness should start before formal obligations take effect. External advisers have recommended that life sciences companies review data due diligence, infrastructure readiness, sensitive health data mapping, and third-party arrangements now, because the secondary-use provisions will become operational from 2029.¹⁰

What pharma needs to build 

But EHDS readiness is not just a compliance exercise. It requires pharma companies to turn health data access into an operational capability, supported by repeatable workflows, governance, and scalable infrastructure. This reflects a broader shift from fragmented, project-based approaches to a more structured and industrialized model for data access and evidence generation.  

The next challenge for pharma is to operationalize this shift in practice. That means putting in place repeatable workflows, clear approvals, strong traceability, and reusable documentation so data access can happen consistently and at scale. 

These capabilities are not optional. The EHDS introduces time-sensitive pressures that pharma teams need to respond to now.

Why this matters now for pharma 

There are four reasons EHDS is a time-sensitive issue for pharma leaders. EHDS should be treated as an operating model shift now, not a distant policy change. 

1. Formalized data use is becoming the norm, as secondary use increasingly depends on governed and traceable access 

2.  The urgency is increasing, with constant pressure for faster innovation and stronger evidence across the product lifecycle   

3. Cross-border collaboration is becoming more complex, requiring repeatable governance models across multiple jurisdictions and partners

4. Strategic preparation is critical, as early readiness improves speed, scalability, and trust 

The EHDS in pharma terms 

The EHDS introduces new actors, workflows, and more structured evidence generation. It establishes a common framework for the use of health data across Europe, distinguishing between primary use in care delivery and secondary use for research, innovation, regulatory, and evidence generation purposes.

In pharma terms, the main shift is from ad hoc data access toward industrialized and governed data access. That means moving from one-off processes and manual coordination toward a more formal model involving data users, health data access bodies, data holders, and secure processing environments.

By standardizing cross-border data access procedures and defining secure server environments for processing pseudonymized patient data across the EU, the EHDS facilitates cross-border research projects where data can come from multiple countries.⁸

For research, innovation, regulation, and evidence generation, this creates a more structured and scalable pathway, but also one that requires operational readiness. 

Why manual governance will not scale with data demand 

Pharma has been steadily increasing its demand for patient data over the past decade, driven by the need to identify trial populations, generate real-world evidence on the effectiveness and safety of therapies, support AI-driven analytics, and provide evidence required for regulatory approval and reimbursement decisions. This demand is further reinforced by growing expectations from regulators and HTA bodies for stronger and more comprehensive real-world evidence.  

This growing demand translates into more frequent and more complex data access requests, often involving multiple data sources, geographies, and use cases. However, the challenge is that traditional, manual workflows do not scale well to meet this demand. As demand grows, teams face more bottlenecks, more governance pressure, greater audit exposure, and longer delays in accessing and using data. These challenges are amplified as secondary use of health data becomes more formalized and regulated under the EHDS. That affects not just research timelines, but also how quickly organizations can generate evidence, collaborate across borders, and support innovation. The pressure is likely to increase further. 

In practice, delays in data access can slow clinical development, real-world evidence generation, and AI programs, ultimately affecting time to market and competitiveness.

That is why pharma leaders should focus on operational readiness now. 

The EHDS operating model 

One of the clearest ways to understand the EHDS is as an operating model for governed data access and evidence generation across Europe

The EHDS standardizes how data can be requested and used across Europe. For pharma, this is less about gaining access to data, and more about being ready to use it efficiently within this new system, for example by enabling faster study setup, more consistent governance, and scalable cross-border data use. 

This model matters because it gives pharma teams a more repeatable path from research question to evidence generation. 

Why current data access models will not scale under the EHDS 

Without a more industrialized model, many organizations will struggle to keep up.  

Current data access and governance models, often based on country-by-country processes, manual approvals, and project-by-project setup, are too slow, too fragmented, and too difficult to sustain at scale. 

 As demand for health data increases and regulatory expectations tighten, these approaches create structural limitations that make it difficult to access and use data efficiently. 

• Manual governance creates inconsistent audit trails and slow approval processes, increasing compliance risk under the EHDS 

• Disjointed tools place the burden of integration on teams, making it harder to access and use data consistently across projects and countries 

• Custom, project-by-project solutions consume legal and technical resources without creating reusable workflows or scalable infrastructure 

• Scaling AI programs requires controlled and traceable data access, making manual and fragmented approaches increasingly unsustainable

What the EHDS-ready pharma looks like 

For pharma leaders, EHDS readiness is not an abstract concept. It reflects a set of operational capabilities that combine governed access, secure analytics, and audit-ready evidence generation. 

An EHDS-ready organization typically has: 

• Governed data access workflows, where data requests, approvals, and usage are managed through repeatable and controlled processes 

• Secure analytics environments, where analysis is performed in controlled settings aligned with data sensitivity and research purpose 

• Audit-ready evidence generation, where access events, approvals, and outputs are fully traceable and ready for compliance review 

• Scalable collaboration models, where new datasets, partners, and studies can be added efficiently through repeatable collaboration patterns 

• Clear traceability across approvals, activity, and outputs, ensuring transparency and control across the full data lifecycle 

These are the capabilities that make data access usable, compliant, and scalable in practice. 

Priority use cases pharma should fund first 

The strongest early use cases are the ones where better data access directly supports research speed, evidence quality, and governance. 

These are practical use cases that connect EHDS readiness directly to business value. They reflect how governed, reusable data access models support faster research, stronger evidence, and more consistent compliance across the product lifecycle.

Business value for pharma leaders 

For leadership teams, the value of EHDS readiness becomes clearer when viewed as an operating improvement. 

In short, the EHDS readiness can improve speed, reduce risk, increase productivity, and make collaboration easier to scale. 

How BC Platforms can help 

We’re here to help with your EHDS journey. We support the EHDS shift by providing the operational building blocks needed to move from fragmented, manual processes to structured, repeatable workflows across the data lifecycle. 

We bring deep scientific and operational experience to this issue, including firsthand insight into how AI can help reduce EHDS-related bottlenecks with capabilities that include: 

• Discovery and feasibility, helping teams identify relevant data assets and assess study viability across datasets and geographies 

• Data harmonization, enabling consistent use of health data through standards such as OMOP and FHIR 

• Access workflows, structuring request, review, approval, and use processes to reduce governance friction and manual effort 

• Secure analysis environments, supporting controlled data access and collaboration while maintaining privacy and compliance 

• Federated analytics, enabling analysis across distributed datasets without requiring data transfer 

• Trusted research environments, providing secure, auditable infrastructure for data use and collaboration 

• Audit generation and traceability, enabling monitoring of access, approvals, and outputs to support compliance and inspection readiness 

• Interoperable data exchange, supporting secure and scalable collaboration across partners and geographies 

From regulation to operating advantage 

 The EHDS is a chance to improve how data is accessed, governed, and used across the research lifecycle. The real advantage comes from being able to operate within it efficiently, through standardized data access, controlled analysis environments, and scalable collaboration models. 

For organizations that are prepared, this enables faster study planning, stronger and more consistent evidence generation, and a more robust foundation for AI-driven research and analytics. 

References 

1. European Commission. European Health Data Space. https://health.ec.europa.eu/ehealth-digital-health-and-care/european-health-data-space_en
2. European Commission. Impact assessment report accompanying the proposal for a Regulation on the European Health Data Space. https://health.ec.europa.eu/publications/impact-assessment-report-european-health-data-space_en
3. Understanding Patient Data. (May 7, 2026). EHDS Unpacked Part One: What Europe’s health data future means for the UK [Webinar]. https://www.youtube.com/watch?v=AGBdxcaCKaA
4. European Medicines Agency. Real‑world evidence. https://www.ema.europa.eu/en/human-regulatory/research-development/real-world-evidence
5. Official Journal of the European Union. (March 5, 2025). Regulation (EU) 2025/327 on the European Health Data Space. https://eur-lex.europa.eu/eli/reg/2025/327/oj/eng
6. BC Platforms. EHDS readiness guide. https://ehds.bcplatforms.com/readiness-guide/
7. HIMSS. (2024). Policy Briefing on the European Health Data Space (EHDS). https://iowa.himss.org/sites/hde/files/media/file/2024/07/24/himss-ehds-fact-sheets-2024.pdf
8. EFPIA. EHDS opportunities and challenges for pharma. https://www.efpia.eu/news-events/the-efpia-view/
9. Kanninen T. (September 12, 2025). How the New European Health Data Space Will Drive the Development of AI-Based Tools. Bio-IT World. https://www.bcplatforms.com/news/how-the-new-european-health-data-space-will-drive-the-development-of-ai-based-tools
10. Sidley Austin. (March 28, 2025). European Health Data Space Regulation Adopted: What’s Next for Life Sciences Companies? https://www.sidley.com/en/insights/publications/2025/03/european-health-data-space-regulation-adopted-whats-next-for-life-sciences-companies
11. Capgemini. (June 11, 2026). European Health Data Space: A new era in healthcare. https://www.capgemini.com/insights/expert-perspectives/what-is-the-european-health-data-space-heres-what-healthcare-leaders-need-to-know/
12. Avalere Health. (August 7, 2025). EHDS aims to transform data access across EU health systems. https://advisory.avalerehealth.com/insights/ehds-aims-to-transform-data-access-across-eu-health-systems